Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections
Journal
Hepatology international
Date Issued
2024-03-09
Author(s)
Chen, Tao
Chen, Guang
Wang, Guiqiang
Treeprasertsuk, Sombat
Lesmana, Cosmas Rinaldi Adithya
Lin, Han-Chieh
Al-Mahtab, Mamun
Chawla, Yogesh K
Tan, Soek-Siam
Yuen, Man-Fung
Lee, Guan-Huei
Alcantara-Payawal, Diana
Nakayama, Nobuaki
Abbas, Zaigham
Jafri, Wasim
Kim, Dong-Joon
Choudhury, Ashok
Mahiwall, Rakhi
Hou, Jinlin
Hamid, Saeed
Jia, Jidong
Bajaj, J S
Wang, Fusheng
Sarin, Shiv K
Ning, Qin
Abstract
End-stage liver disease (ESLD) is a life-threatening clinical syndrome and when complicated with infection the mortality is markedly increased. In patients with ESLD, bacterial or fungal infection can induce or aggravate the occurrence or progression of liver decompensation. Consequently, infections are among the most common complications of disease deterioration. There is an overwhelming need for standardized protocols for early diagnosis and appropriate management for patients with ESLD complicated by infections. Asia Pacific region has the largest number of ESLD patients, due to hepatitis B and the growing population of alcohol and NAFLD. Concomitant infections not only add to organ failure and high mortality but also to financial and healthcare burdens. This consensus document assembled up-to-date knowledge and experience from colleagues across the Asia-Pacific region, providing data on the principles as well as evidence-based current working protocols and practices for the diagnosis and treatment of patients with ESLD complicated by infections.
Subjects
ACLF; Acute decompensation; Antibiotics; Cirrhosis; Consensus; Decompensation; Infection; Organ failure; Sepsis; Septic shock; Treatment
SDGs
Type
editorial